13 Red Days In A Row: BridgeBio Pharma Stock Is Down 11%
A persistent slide in this biotech stock has erased significant value, focusing attention on a business with a starkly mixed financial profile.
A thirteen-day slide in BridgeBio Pharma (BBIO) stock has erased about $1.8 billion from the company’s market value. The stock has now moved lower for 13 consecutive trading days, shedding a cumulative 10.9% over that period and bringing its market capitalization to about $15 billion.
For anyone holding the stock, this persistent selling pressure has been significant. The move has also pushed the stock’s one-month return to -11.5%, though its return over the trailing twelve months remains +40.1%.
The Streak Next To The S&P 500
Here is how BBIO stock stacks up against the S&P 500 over the streak and the periods around it:
| Return Period | BBIO | S&P 500 |
|---|---|---|
| 1D | -0.1% | -0.6% |
| 13D (Current Streak) | -10.9% | -0.4% |
| 1M (21D) | -11.5% | -1.1% |
| 3M (63D) | 11.0% | 3.6% |
| YTD 2026 | -2.3% | 12.1% |
| 2025 | 178.8% | 16.4% |
| 2024 | -32.0% | 23.3% |
| 2023 | 429.8% | 24.2% |
The numbers show a business with deep operational losses.
While the immediate catalyst for the 13-day selloff is not evident from the data, the move comes on the heels of a mid-August secondary offering in which KKR Genetic Disorder L.P. sold 5 million existing shares—about 2.6% of shares outstanding—adding supply to the active float even as BridgeBio received no proceeds. More broadly, the decline unfolds against a difficult financial baseline: an operating margin of -67.0% over the last twelve months, well below the S&P 500 median of 18.6%, alongside ongoing negative earnings. This selling streak is the stock’s own story; over the same 13 trading days, the S&P 500 returned -0.4%.
Yet this comes alongside extremely high growth. Revenue over the last twelve months grew 202.4%, far outpacing the S&P 500 median of 8.4%. The company’s 3-year average annual revenue growth is 1323.7%.
How should an investor treat a streak?
A streak is not an instruction. It is information, telling you that a stock has captured the market’s attention and that momentum, in this case downward, has been persistent. It does not, by itself, tell you if a stock is a buy or a sell.
The disciplined response is to use the attention as a prompt to check the business against its price. The data here shows a company with a clear conflict between its revenue growth and its current profitability. That is the fundamental tension an investor must resolve.
If the drop has you weighing an entry, resist buying on the discount alone. Our Buy the Dip screen ranks the marked-down names where growth and cash generation still support a recovery.
And for anyone who would rather back the theme than one company’s story, a biotech ETF like XBI holds the sector rather than this one name. It is still a concentrated bet on that one theme, though, which is exactly the gap the portfolio below closes.
Weakness In One Name Should Be Noise, Not News
For a diversified holder, a streak like this is a data point. For a concentrated one, it is a hole in the plan. The difference is never the stock; it is the portfolio built around it.
Building that portfolio is what the Trefis High Quality (HQ) Portfolio does: roughly 30 businesses with the cash generation and balance-sheet strength to absorb a bad month, selected and rebalanced by rules. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Make the next streak, in either direction, someone else’s drama.